Analysts’ Weekly Ratings Changes for Alnylam Pharmaceuticals (ALNY)

A number of firms have modified their ratings and price targets on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) recently:

• 7/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Bank of America Corporation from $460.00 to $410.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Alnylam Pharmaceuticals had its price target lowered by Truist Financial Corporation from $505.00 to $410.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Alnylam Pharmaceuticals had its price target raised by HC Wainwright from $470.00 to $485.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Alnylam Pharmaceuticals had its price target raised by Morgan Stanley from $370.00 to $400.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/29/2026 – Alnylam Pharmaceuticals had its price target lowered by HC Wainwright from $510.00 to $470.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/21/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/13/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/4/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $510.00 price target on the stock.
• 5/19/2026 – Alnylam Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $380.00 price target on the stock.
• 5/18/2026 – Alnylam Pharmaceuticals was upgraded by Citigroup Inc. to “strong-buy”.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Get Alnylam Pharmaceuticals Inc alerts:

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

See Also

• Five stocks we like better than Alnylam Pharmaceuticals
• Why Conagra’s Dividend Cut Could Be the Best Thing for Investors
• Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money
• Cintas Keeps Beating Expectations—And the Story Isn’t Over
• Which Storage Stock Is Best Positioned to Win the AI Memory War?

Receive News & Ratings for Alnylam Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.